### STROBE Statement—Checklist of items that should be included in reports of cohort studies

<table>
<thead>
<tr>
<th>Item No</th>
<th>Title and abstract</th>
<th>Recommendation</th>
<th>Reported on page no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(a) Indicate the study’s design with a commonly used term in the title or the abstract</td>
<td>Title Page 1-2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</td>
<td>1-2</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Introduce the scientific background and rationale for the investigation being reported</td>
<td>2-3</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>State specific objectives, including any prespecified hypotheses</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Present key elements of study design early in the paper</td>
<td>3-4</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</td>
<td>3-5</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</td>
<td>3-7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(b) For matched studies, give matching criteria and number of exposed and unexposed</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</td>
<td>3-7</td>
<td></td>
</tr>
<tr>
<td>8*</td>
<td>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</td>
<td>3-7</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Describe any efforts to address potential sources of bias</td>
<td>3-7</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Explain how the study size was arrived at</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>(a) Describe all statistical methods, including those used to control for confounding</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(b) Describe any methods used to examine subgroups and interactions</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(c) Explain how missing data were addressed</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(d) If applicable, explain how loss to follow-up was addressed</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(e) Describe any sensitivity analyses</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>13*</td>
<td>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(b) Give reasons for non-participation at each stage</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(c) Consider use of a flow diagram</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td>14*</td>
<td>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(b) Indicate number of participants with missing data for each variable of interest</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(c) Summarise follow-up time (eg, average and total amount)</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>15*</td>
<td>Report numbers of outcome events or summary measures over time</td>
<td>6-7</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Item</td>
<td>Recommendation</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Main results</strong></td>
<td>16</td>
<td>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(b) Report category boundaries when continuous variables were categorized.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.</td>
<td></td>
</tr>
<tr>
<td><strong>Other analyses</strong></td>
<td>17</td>
<td>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses.</td>
<td></td>
</tr>
<tr>
<td><strong>Discussion</strong></td>
<td>18</td>
<td>Summarise key results with reference to study objectives.</td>
<td></td>
</tr>
<tr>
<td><strong>Limitations</strong></td>
<td>19</td>
<td>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.</td>
<td></td>
</tr>
<tr>
<td><strong>Interpretation</strong></td>
<td>20</td>
<td>Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.</td>
<td></td>
</tr>
<tr>
<td><strong>Generalisability</strong></td>
<td>21</td>
<td>Discuss the generalisability (external validity) of the study results.</td>
<td></td>
</tr>
<tr>
<td><strong>Other information</strong></td>
<td>22</td>
<td>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.</td>
<td></td>
</tr>
</tbody>
</table>

*Give information separately for exposed and unexposed groups.